Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis’ canakinumab fails to meet primary endpoint in lung cancer trial

pharmaceutical-technologyMarch 10, 2021

Tag: Novartis , canakinumab , NSCLC , CANOPY-2

PharmaSources Customer Service